---
title: "durvalumab"
slug: "durvalumab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[Pathologic stage IIIA (N2) to IIIB disease of NSCLC Treatment]]

# durvalumab

- Mechanism: Binds to PDL-1
- Dosing: 10 mg/kg every 2 wks
- PK/PD: T1/2 âˆ¼18 d
- AEs:
  - Immune-mediated tox,
  - infusion rxn,
  - skin rash,
  - metabolic abnormalities,
  - hypothyroidism,
  - diarrhea,
  - lymphocytopenia,
  - â†‘ liver enzymes,
  - fatigue,
  - cough
- DDI: No known pathways of metabolism, avoid corticosteroids since it may diminish the therapeutic effect of immune checkpoint inhibitors
- Clinical pearls: Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d)

## ä½œç”¨æ©Ÿè½‰

Durvalumab æ˜¯ï¼šå±¬æ–¼ PD-L1 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘

- T æ·‹å·´ç´°èƒ ï¼ˆT ç´°èƒï¼‰ ä¸Šæœ‰è¨±å¤šå…ç–«æª¢æŸ¥é»ï¼Œæœ‰äº› æ˜¯ï¼šä¿ƒé€²å®ƒå€‘æ´»åŒ–å°±åƒè¸©æ²¹é–€ï¼Œæœ‰äº›åè€Œ æ˜¯ï¼šæŠ‘åˆ¶å®ƒå€‘å°±åƒè¸©ç…è»Šï¼Œå…¶ä¸­ PD-1 æ˜¯ï¼šå±¬æ–¼æŠ‘åˆ¶æ€§å…ç–«æª¢æŸ¥é»ã€‚

æ­¤å¤–ï¼Œç•¶ T ç´°èƒé è¿‘ç™Œç´°èƒæ™‚ï¼Œç™Œç´°èƒæ™‚å¸¸æœƒå‡ºç¾ PD-L1 é…é«”ï¼Œç•¶ PD-L1 å’Œ PD-1 çµåˆå¾Œæœƒå°è‡´ T ç´°èƒ âœ– ç„¡æ³•ç™¼æ®åŠŸèƒ½ï¼Œè€Œ PD-L1 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘å‰‡å¯æŠ‘åˆ¶ PD-1 å’Œ PD-L1 çµåˆï¼Œä¹Ÿå°± æ˜¯ï¼šæ‹¿æ‰ç…è»Šï¼Œé‡æ–°å–šé†’ T ç´°èƒç™¼æ®å…¶æŠ—ç™Œä½œç”¨ã€‚

## é©æ‡‰ç—‡

éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€æ³Œå°¿é“ä¸Šçš®ç™Œã€‚

## ç”¨æ³•ç”¨é‡

æ¯ä¸‰è‡³å››é€±ä¸€æ¬¡ï¼Œæ¯æ¬¡çµ¦äºˆ 1500 mg æˆ– 20 mg/kg

- ä¹Ÿå¯æ¯å…©é€±ä¸€æ¬¡ï¼Œæ¯æ¬¡çµ¦äºˆ 10 mg/kgã€‚

## å‰¯ä½œç”¨

1. å¸¸è¦‹
   ç–²å€¦(32-39%)ã€ä¾¿ç§˜(17-21%)ã€è‚Œè‚‰éª¨éª¼ç—›(24%)ã€å’³å—½(10-40%)ã€çš®ç–¹(11-26%)

2. åš´é‡
   å¿ƒè‚Œç‚ã€è…ä¸Šè…ºåŠŸèƒ½ âœ– ä¸è¶³(0.5-0.7%)ã€ç”²ç‹€è…ºåŠŸèƒ½ä½ä¸‹/è…¦ä¸‹å‚é«”ç™¼ç‚(5.5-11%)ã€å¤§è…¸ç‚/è…¹ç€‰(10-18%)ã€è‚ºéƒ¨ç™¼ç‚(2.3%)ã€è‚ç‚(1.1-12%)
